Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
122.87
Dollar change
-1.58
Percentage change
-1.27
%
Index- P/E- EPS (ttm)-6.16 Insider Own5.96% Shs Outstand93.73M Perf Week-2.55%
Market Cap11.53B Forward P/E11.15 EPS next Y11.01 Insider Trans0.92% Shs Float88.26M Perf Month0.75%
Income-535.98M PEG- EPS next Q-0.06 Inst Own86.80% Short Float5.21% Perf Quarter5.87%
Sales1.24B P/S9.28 EPS this Y140.93% Inst Trans6.40% Short Ratio5.08 Perf Half Y-1.51%
Book/sh9.17 P/B13.40 EPS next Y363.98% ROA-16.77% Short Interest4.60M Perf Year-11.67%
Cash/sh17.86 P/C6.88 EPS next 5Y- ROE-86.15% 52W Range55.25 - 159.89 Perf YTD27.42%
Dividend Est.- P/FCF- EPS past 5Y-1.21% ROI-25.13% 52W High-23.15% Beta0.95
Dividend TTM- Quick Ratio3.45 Sales past 5Y32.89% Gross Margin84.34% 52W Low122.39% ATR (14)3.42
Dividend Ex-Date- Current Ratio3.95 EPS Y/Y TTM24.04% Oper. Margin-21.54% RSI (14)40.92 Volatility2.22% 2.56%
Employees1314 Debt/Eq1.63 Sales Y/Y TTM33.26% Profit Margin-43.11% Recom1.48 Target Price166.32
Option/ShortYes / Yes LT Debt/Eq1.48 EPS Q/Q134.77% Payout- Rel Volume0.73 Prev Close124.45
Sales Surprise2.48% EPS Surprise582.15% Sales Q/Q53.54% EarningsFeb 28 AMC Avg Volume904.15K Price122.87
SMA20-2.78% SMA50-3.24% SMA20010.60% Trades Volume656,027 Change-1.27%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Initiated BMO Capital Markets Outperform $170
Dec-13-23Resumed Citigroup Buy $113
Dec-12-23Initiated Deutsche Bank Buy $109
Nov-21-23Initiated Wedbush Outperform $224
Oct-31-23Downgrade Oppenheimer Outperform → Perform
Oct-31-23Downgrade Cantor Fitzgerald Overweight → Neutral $166 → $40
Jun-23-23Downgrade Evercore ISI Outperform → In-line $139
Apr-26-23Initiated SMBC Nikko Outperform $185
Apr-04-23Initiated Citigroup Buy $179
Mar-01-23Upgrade Morgan Stanley Equal-Weight → Overweight $141 → $187
Apr-08-24 04:13PM
Apr-06-24 08:45AM
Apr-02-24 07:04AM
Mar-29-24 04:00PM
11:30AM
07:49AM Loading…
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
12:05AM Loading…
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Feb-28-24 06:00PM
04:23PM
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
11:23AM Loading…
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Nov-09-23 10:00AM
Nov-08-23 10:15AM
Nov-07-23 11:23PM
Nov-02-23 06:25PM
12:18PM
08:30AM
12:00AM
Nov-01-23 05:03PM
04:29PM
04:05PM
Oct-31-23 07:02PM
04:19PM
04:07PM
03:03PM
11:52AM
10:26AM
10:21AM
09:38AM
09:19AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boor Kathryn JeanDirectorMar 11 '24Sale122.9376193,5507,516Mar 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Option Exercise13.9015,000208,50037,840Mar 11 08:02 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Sale123.2515,0001,848,79522,840Mar 11 08:02 PM
Mayo StephenDirectorMar 05 '24Sale122.963,135385,4806,621Mar 06 08:00 PM
Arif BilalChief Tech Ops OfficerMar 01 '24Sale128.842,000257,67626,836Mar 05 08:00 PM
Brown Ryan EdwardEVP, General CounselMar 01 '24Sale125.342,000250,68031,827Mar 05 08:00 PM
Estepan Ian MichaelChief Financial OfficerMar 01 '24Sale128.301,200153,96039,114Mar 05 08:00 PM
BEHRENS M KATHLEENDirectorNov 03 '23Option Exercise29.0315,000435,450174,993Nov 06 08:00 AM
Barry RichardDirectorNov 03 '23Buy78.8150,0003,940,500140,000Nov 06 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 03 '23Buy79.3625,2252,001,800390,307Nov 06 08:00 AM
Chambers Michael AndrewDirectorAug 14 '23Buy109.479,9791,092,429246,996Aug 15 08:00 AM
Chambers Michael AndrewDirectorAug 11 '23Buy108.0523,6862,559,272237,017Aug 14 08:00 AM
Chambers Michael AndrewDirectorAug 10 '23Buy106.1534,8673,701,067213,331Aug 11 07:40 AM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Option Exercise29.0315,000435,45035,994Aug 08 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Sale106.7215,0001,600,80020,994Aug 08 08:00 PM